(Reuters) -GSK said on Thursday it had expanded its agreement with China’s largest vaccine company Zhifei to explore a potential collaboration on the British drugmaker’s respiratory syncytial virus (RSV) vaccine, Arexvy. Last year, London-listed GSK said Zhifei would pay it 2.5 billion pounds ($3.18 billion) for the exclusive rights to distribute GSK’s shingles vaccine, Shingrix, […]
(Reuters) -GSK said on Thursday it had expanded its agreement with China’s largest vaccine company Zhifei to explore a potential collaboration on the British drugmaker’s respiratory syncytial virus (RSV) vaccine, Arexvy.
Last year, London-listed GSK said Zhifei would pay it 2.5 billion pounds ($3.18 billion) for the exclusive rights to distribute GSK’s shingles vaccine, Shingrix, in the world’s No.2 pharmaceuticals market .
GSK said on Thursday it has revised the terms on which Zhifei will commercialise Shingrix in China to 2034.
Under the revised agreement, Zhifei has also agreed to engage exclusively with GSK to explore a potential collaboration on Arexvy, with an initial term of 10 years.
The companies expect that Zhifei will purchase volumes of Shingrix, phased over time, with a potential total value to GSK of 2.3 billion pounds ($2.93 billion) over the six-year period from 2024 to 2029.
($1 = 0.7860 pounds)
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D’Souza and Rashmi Aich)
